The next-generation mRNA-1283 vaccine is estimated to be highly cost-effective and dominate original mRNA vaccines at a $100,000-150,000 per QALY threshold in the US.
Is the next-generation COVID-19 mRNA-1283 vaccine cost-effective compared to originally-licensed mRNA vaccines in the US?
The next-generation mRNA-1283 COVID-19 vaccine is projected to be a highly cost-effective alternative to originally-licensed mRNA vaccines in the US.
Absolute Event Rate: 0% vs 0%
Study results suggest mRNA-1283 may represent a highly cost-effective strategy (considering a 100, 000-150, 000 per QALY willingness-to-pay threshold) to reduce COVID-19 burden. Based on rVE assumptions made, mRNA-1283 was estimated to dominate originally-licensed mRNA vaccines in this recommended population. mRNA-1283 may provide a valuable option to optimize US COVID-19 immunization programs and protect those most vulnerable.
Fust et al. (Tue,) reported a other. The next-generation mRNA-1283 vaccine is estimated to be highly cost-effective and dominate original mRNA vaccines at a $100,000-150,000 per QALY threshold in the US.